[25] Higher dosages do not have proven benefit and may increase the risk of adverse effects. In duloxetine studies for any indication, there seem to be dosage-related adverse effects. The authors ...

Certain bottles and doses of duloxetine, a common antidepressant, have been recalled due to the presence of potentially cancer-causing chemicals. The recall was initiated on Nov. 19 by ...

On Nov. 19, various doses of duloxetine delayed-release capsules manufactured by Rising Pharma, Inc., were recalled due to the "presence of N-nitroso-duloxetine impurity above [the] recommended ...

More than 233,000 bottles of duloxetine capsules sold by Rising Pharmaceuticals were voluntarily recalled on Nov. 19, and the U.S. Food and Drug Administration assigned the recall as a class II ...

The recall includes several different formulations of duloxetine delayed-release capsules. The impacted lots cover 20 mg, 30 mg, and 60 mg dosages, across various bottle sizes ranging from 30 to ...

The U.S. Food and Drug Administration classified capsules of duloxetine, sold by New Jersey-based company Rising Pharmaceuticals, as a Class II risk on Dec. 5. The risk level is the FDA's second ...

The capsules of duloxetine were first recalled in November, but the FDA recently categorized the recall as a Class II risk, a situation in which "use of or exposure to a violative product may ...

The U.S. Food and Drug Administration classified capsules of duloxetine, sold by New Jersey-based company Rising Pharmaceuticals, as a Class II risk on Dec. 5. The risk level is the FDA's second most ...

The recall affected over 233,003 30-count, 90-count and 1,000-count bottles of 60 mg Duloxetine capsules. The FDA does not suggest that patients stop taking Duloxetine immediately but instead talk ...

More than 233,000 bottles of duloxetine capsules sold by Rising Pharmaceuticals were voluntarily recalled on Nov. 19, and the U.S. Food and Drug Administration assigned the recall as a class II risk ...